IDH’s operations network extends beyond Egypt to Jordan, Sudan, and Nigeria. As of December 2022, IDH had 552 lab branches, up by 50 branches compared to 2021. It completed 32.7 million tests in 2022. The company served 8.7 million patients last year, a 16% decrease compared to 2021. El Sherbini has been the IDH Group’s CEO since 2012. The company is listed on the London Stock Exchange.